Protocol 405 -201-[ZIP_CODE]
2
Confidential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012833] of In-text Figures .................................................................................... 8
1 Protocol Summary ................................................................................ 9
1.1 Synopsis...............................................................................................................9
1.2 Schema ..............................................................................................................15
1.3 Schedule of Assessments ...................................................................................16
2 Introduction ................................
........................................................ 18
2.1 Trial Rationale ...................................................................................................19
2.2 Background .......................................................................................................19
2.2.2 Clinical ............................................................................................................20
2.3 Known and Potential Risks and Benefits ..........................................................21
3 Objectives and Endpoints ...............................................................
...23
4 Trial Design ......................................................................................... 24
4.1 Type/Design of Trial .........................................................................................[ADDRESS_1012834] Selection and Numbering .....................................................................25
5.2 Eligibility  Criteria
................................ ................................ .............................. 26
5.2.1 Inclusion Criteria ................................ ................................ ............................ 26
5.2.2 Exclusion Criteria ................................ ................................ ........................... 27
5.3 Lifesty le Considerations ................................ ................................ .................... 29
5.3.2 Caffeine, Alcohol, and Tobacco .....................................................................30
5.3.3 Activity ................................ ................................ ................................ ........... 30
5.4 Screen Failures ................................ ................................ ................................ ..30Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
2

Protocol 405 -201-[ZIP_CODE]
3
Confidential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012835] Quality  Complaints ................................ ...................... 33
[IP_ADDRESS] Eliciting and Reporting Product Quality  Complaints .................................33
[IP_ADDRESS] Information Required for Reporting Purposes ............................................33
[IP_ADDRESS] Return Process .............................................................................................34
[IP_ADDRESS] Assessment/Evaluation ...............................................................................34
6.3 Measures to Minimize/Avoid Bias ....................................................................[ADDRESS_1012836] to Follow -
up................................ .......................... 38
8 Trial Procedures ................................................................................. 38
8.1 Efficacy  Assessments ................................ ................................ ........................ 38Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
3

Protocol 405 -201-[ZIP_CODE]
4
Confidential -Proprietary Information Amendment 1 Approval: 23 Jul [ZIP_CODE].2.1 Pharmacokinetic Blood Samples ....................................................................39
8.3 Pharmacod ynamic Assessments ........................................................................39
8.4 Pharmacogenomic Assessments ........................................................................39
8.5 Biomarker Assessments ................................ ................................ .................... 39
8.6 Future Biospecimen Research Samples ............................................................40
8.7 Safety  Assessments ...........................................................................................40
8.7.1 Clinical L aboratory  Assessments ...................................................................40
8.7.2 Physical Examination .....................................................................................40
8.7.3 Vital Signs ......................................................................................................41
8.7.4 Electrocardiogram ...........................................................................................41
8.7.5 Suicidality  Monitoring ....................................................................................41
8.7.6 Other Safet y Variables ....................................................................................42
8.8 Adverse Events ..................................................................................................42
8.8.1
Definitions ......................................................................................................42
8.8.2
Eliciting and Reporting Adverse Events.........................................................44
8.8.3 Immediately
 Reportable Events ......................................................................45
8.8.4 Medical 
Device Incidents (Including Malfunctions) ......................................[ADDRESS_1012837] .................................................................45
8.8.6 Potential Serious Hepatotoxicity ....................................................................45
8.8.7 Procedure for Breaking the Blind ...................................................................45
8.8.8 Follow -up of Adverse Events .........................................................................46
[IP_ADDRESS] Follow -up of Nonserious Adverse Events ..................................................46
[IP_ADDRESS] Follow -up of Immediately  Reportable Events ................................ ............ 46
[IP_ADDRESS] Follow -up and Reporting of I mmediatel y Reportable Events 
Occurring After Last Scheduled Contact ....................................................[ADDRESS_1012838] ................................ ................................ ..................... 47
9 Statistical Considerations .................................................................. 47
9.1 Sample Size .......................................................................................................47Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
4

Protocol 405 -201-[ZIP_CODE]
5
Confidential -Proprietary Information Amendment 1 Approval: 23 Jul [ZIP_CODE].2 Datasets for Anal ysis.........................................................................................48
9.3 Hand ling of Missing Data for Primary  and Other Endpoint Analy sis..............48
9.4 Statistical Analy ses............................................................................................48
9.4.1 Efficacy  Anal yses...........................................................................................48
9.4.2 Safety  Anal ysis...............................................................................................48
[IP_ADDRESS] Adverse Events ............................................................................................48
[IP_ADDRESS] Clinical L aboratory  Data .............................................................................48
[IP_ADDRESS] Physical Examination and Vital Signs Data ................................................49
[IP_ADDRESS] Electrocardiogram Data ..............................................................................49
[IP_ADDRESS] Other Safet y Data ........................................................................................49
[IP_ADDRESS].1 Columbia -Suicide Severity  Rating Scale ................................................49
9.4.3 Other Anal yses................................................................................................49
[IP_ADDRESS] Analy sis of Demographic and Baseline Characteristics ............................. 49
[IP_ADDRESS] Pharmacokinetic Analy sis...........................................................................49
[IP_ADDRESS] Pharmacod ynamic Anal ysis........................................................................50
[IP_ADDRESS] Pharmacokinetic/Pharmacody namic Anal ysis............................................50
[IP_ADDRESS] Pharmacogenomic Anal ysis........................................................................50
[IP_ADDRESS] Exploratory
 Endpoint Analy sis...................................................................50
[IP_ADDRESS] Other Endpoint Anal ysis.............................................................................50
9.5 Interim Anal ysis and Adaptive Design
.............................................................50
9.5.1 Data Monitoring Committee ...........................................................................50
10 Supporting Documentation and Operational Considerations .......51
10.1 Appendi x 1: Regulatory , Ethical, and Trial Oversight Considerations .............51
10.1.1 Ethics and Responsibility ................................ ................................ ............... 51
10.1.2 Informed Consent ................................ ................................ ........................... 51
10.1.3 Confidentiality ................................ ................................ ................................ 53
10.1.4 Quality  Control and Quality  Assurance ................................ .......................... 53
[IP_ADDRESS] Monitoring ..................................................................................................53
[IP_ADDRESS] Auditing ................................ ................................ ................................ ......53
10.1.5 Protocol Deviations ................................ ................................ ........................ 54
10.1.6 Records Management ................................ ................................ ..................... 54
[IP_ADDRESS] Source Documents ................................ ................................ ...................... 54Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
5
Protocol 405 -201-[ZIP_CODE]
6
Confidential -Proprietary Information Amendment 1 Approval: 23 Jul 201910.1.6.2 Data Collection ............................................................................................54
[IP_ADDRESS] File Management at the Trial Site ...............................................................56
[IP_ADDRESS] Records Retention at the Trial Site .............................................................56
[IP_ADDRESS] Publication Authorship Requirements ........................................................57
10.2 Appendi x 2: Clinical L aboratory  Tests .............................................................58
10.3 Appendix 3: Contraceptive Guidance and Collection of Pregnancy  
Information ........................................................................................................59
10.4
Appendix 4: Abbreviations ...............................................................................61
10.5 Appendix 5: Criteria for Identify ing Laboratory  Values of Potential 
Clinical Relevance .............................................................................................63
10.6 Appendix 6: Criteria for Identify ing Vital Signs of Potential Clinical 
Relevance ..........................................................................................................64
10.7 Appendix 7: Criteria for Identify
ing ECG Measurements of Potential 
Clinical Relevance .............................................................................................65
10.8 Appendix 8: Protoco l Amendments ..................................................................66
11 References ...............................................................
............................. 69Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
6

Protocol 405 -201-[ZIP_CODE]
7
Confidential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012839] of In
-text Tables
Table 1.3-1 Schedule of Assessments .............................................................. 16
Table 3
-1 Trial Objectives and Endpoints ..................................................... 23
Table 10.2
-1 Clinical L aboratory  Assessments .................................................. 58Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
7
Protocol 405 -201-[ZIP_CODE]
9
Confidential -Proprietary Information Amendment 1 Approval: 23 Jul [ZIP_CODE] Protocol Summary
1.1 Synopsis
Name [CONTACT_658825]:Otsuka Pharmaceutical Development & Commercialization, I nc.
Name [CONTACT_92732]: Centanafadine (EB -
1020)
Protocol No.: 405-201- [ZIP_CODE]
IND No.: 119361
Protocol Title :A Pi[INVESTIGATOR_42751] 2a, Multicenter, Open
-label, Single -dose Trial to Assess 
the Pharmacokinetics of Centanafadine Extended -release Capsules After Oral 
Administration in Pediatric Subjects (9 to 12 years, inclusive) With Attention- deficit 
Hyperactivity  Disorder
Protocol Lay Person Short Title :Open -label, Single -dose Trial t o Assess the 
Pharmacokinetics of Centanafadine Extended -release Capsules in Pediatric Subjects With 
Attention- deficit Hy peractivity  Disorder
Clinical Phase: 2a
Treatment/Indication: Attention- deficit hyperactivity  disorder (ADHD)
Objectives and Endpoints:
Objectives Endpoints
Primary :
To characterize the single -dose 
concentration -time profile from 0 to 
12 hours of centanafadine in pediatric 
subjects (9 to 12 years, inclusive) 
with ADHD.Primary :
Cmaxof centanafadine
tmaxof centanafadine
AUC 0-12h of centanafadine
Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
9
Protocol 405 -201-[ZIP_CODE]
11
Confidential -Proprietary Information Amendment 1 Approval: 23 Jul 2019Eligible subjects will check- in either on Day  −1 or Day  1, based on the investigator’s 
decision. A single dose of centanafadine will be administered either as intact capsule sor 
the capsule contents sprinkled on a tablespoon of applesauce on Day  1 in the morning. 
 
 Pharmacokinetic (PK) and safet y assessments will be 
performed for approximately  24hours postdose. Subjects may  be released from the clinic 
after PK sample collection at 12 hours postdose to return the following morning or may  
remain in the clinic until 24 hours postdose, base d on the investigator’s decision. Subjects 
released on Day  [ADDRESS_1012840] the clinic on Day 2 after EoT assessments and PK sampling are 
complete. 
Subjects and/or their caregivers will be contact[CONTACT_424362] 7 day s after dosing to 
assess an y new or ongoing adverse events (AEs) and to record concomitant medications.
Trial Population:
The trial po pulation will consist of males and females, aged 9 to 12 years (inclusive)
,
who have a documented history  of ADHD and confirmation of anADHD prescription 
medication . Up to 12 subjects may  be treated in the trial .
Key Inclusion/Exclusion Criteria:
Key inclusion criteria are noted above, under Trial Population. In addition, subjects must 
be in good ph ysical health, as determined by  [CONTACT_740885], prior to enrollment in the trial:
Medical history
Clinical laboratory  determination
Electrocardiograms (ECGs)
Physical examinations
Key exclusion criteria are as follows:
Subjects with a clinical presentation or history
 that is consistent with delirium, 
dementia, amnesia, or other cognitive disorders; subjects with psy chiatric sy mptoms 
that are better accounted for b y another general medical condition(s) or direct effect 
of a substance (ie, medication, illicit drug use, etc.).
Subjects with a history  of intellectual disability  as determined b y at least 1 of the 
following: an intelligence quotient ( IQ)< 70, or clinical evidence, or a social or 
school history  that is suggestive of an intellectual disability .Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
11

Protocol 405 -201-[ZIP_CODE]
12
Confidential -Proprietary Information Amendment 1 Approval: 23 Jul 2019Subjects who have an y of the following:
A significant risk of committing suicide based on history  and the 
principal 
investigator ’s clinical judgment, or routine psy chiatric status examination
Current suicidal behavior
Imminent risk of injury  to self
Active suicidal ideation as it is evidenced b yan answer of “y es” on Questions 4 
or 5 (over the last 6 months) on the suicidal ideation section of the 
“Baseline/Screening” version of the Columbia -Suicide Severit y Rating Scale
(C-SSRS )
Any lifetime history  of suicidal behavior detected by  [CONTACT_941] “Baseline /Screening” 
version of the C -SSRS
The subject should not be enrolled (eg, dosed) if any  active suicidal ideation is 
present prior to dosing (as evidenced b y a clinical examination or an answer of “y es” 
on Questions 4 or 5 of the C -SSRS “Since L ast Visit” v ersion) or suicidal behavior is 
present in the C -SSRS “Since Last Visit” version.
Subjects who have supi[INVESTIGATOR_740877], after resting for at 
least 5 minutes, ≥ 95 mmHg.
Subjects who participated in a clinical trial and were exposed to investigational 
medicinal product ( IMP)within the last [ADDRESS_1012841] y ear.
Subjects with a history  of true allergic response (ie, not intolerance) to a medi cation 
or a history  of dermatologic adverse reactions or anaphy laxis secondary  to drug 
exposure.
Subjects with a history  of allergic reaction or a known or suspected sensitivity  to an y 
substance that is contained in the I MP formulation.
Trial Site(s):
This will be a multicenter trial (at 
approximately  3 trial sites) conducted in the 
[LOCATION_002].
Investigational Medicinal Product(s), Dose, Dosage Regimen, Treatment Duration, 
Formulation, Mode of Administration:
Centanafadine will be supplied as [ADDRESS_1012842] . A 
snack will be provided approximately  2hours after dosing and lunch will be provided 
approximately  4 hours after dosin g. Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
12

Protocol 405 -201-[ZIP_CODE]
14
Confidential -Proprietary Information Amendment 1 Approval: 23 Jul 2019Trial Duration:
Each subject in t
his trial is expected to participate in the following periods of the trial 
(approximate durations listed) , for up to 29 (+ 2) day s:
Eligibility  screening period: 21 day s (including optional check -in on Day  −1)
Treatment period : 2 day s (Day  1: dosing, Day  2: EoT)
Post-treatment follow -
up:7 (+ 2) day s after the last dose of IMP
Overall, the trial duration from the first informed consent /assent to the final subject
assessment is expected to be 3 months.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
14
Protocol 405 -201-[ZIP_CODE]
16
Confidential -Proprietary Information Amendment 1 Approval: 23 Jul [ZIP_CODE].3 Schedule of A ssessments
Table 1.3-1 Schedule of Assessments
AssessmentScreeningaCheck -inb Treatm ent Discharge Follow -up 
Telephone CallcNotes
Day −21 to Day −2 Day −1 Day 1 Day 2/EoT/ET Day 8 (+ 2)
Screening
Informed consent /assent X Section 10.1.2
Inclusion/exclusion criteria check X Section 5.2
Dem ographic information X
Medical history X
Height X Section 8.7.2
Serology (HIV, HBsAg, anti -HCV) X
Breath or urine alcohol test and urine drug 
screenX Section 10.[ADDRESS_1012843] (for FOCBP) X XXd X Section 10.[ADDRESS_1012844] concomitant medications X X X X X Section 6.5
Body  weight X XXd X Section 8.7.2
Physical examination X XXd X Section 8.7.2
Vital signs XXfXf X Section 8.7.3
12-lead ECG X XXd X Section 8.7.4
Serum chemistry, hematology, and urinalysis X XXd X Section 8.7.1
Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
16

Protocol 405 -201-[ZIP_CODE]
17
Confidential -Proprietary Information Amendment 1 Approval: 23 Jul 2019Table 1.3-1 Schedule of Assessments
AssessmentScreeningaCheck -inb Treatm ent Discharge Follow -up 
Telephone CallcNotes
Day −21 to Day −2 Day −1 Day 1 Day 2/EoT/ET Day 8 (+ 2)
C-SSRS X XXd X Section 8.7.5
Pharm acokinetics
Centanafadine ) plasma 
concentrationsX X Section 8.2.1
Other Procedures
anti-HCV =hepatitis C antibodies ; FOCBP = f emales of childbearing potential ;HBsAg =hepatitis B surface antigen .
aThe screening period may be extended if additional time is needed to complet e screening procedures , upon discussion with and approval by [CONTACT_35011].
bEligible subjects will check -in either on Day −1 or Day 1, based on the investigator’s decision.
cA follow -up telephone call will be performed 7 (+ 2) days after dosing
to assess AEs and record concomitant medications .
dDay 1 predose assessments will be performed only for those subjects who check -in on Day 1 (ie, subjects who check -in on Day −[ADDRESS_1012845] their predose 
assessments on Day −1).
eSubjects may be released from the clinic after PK sample collection at 12 hours postdose to return the following morning or may remain in the clinic until 
24hours postdose, based on the investigator’s decision. Subjects released on Day [ADDRESS_1012846] the clinic on Day 2 after the EoT assessments and 
PK sampling arecomplete.
fVital signs will be assessed for all subjects at check -in, predose (within 2 hours before dosing ) on Day 1, and 3hours postdose on Day 1.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
17

Protocol 405 -201-[ZIP_CODE]
18
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul [ZIP_CODE] Introduction
Attention
-deficit hyperactivity  disorder (ADHD) is typi[INVESTIGATOR_1306] y viewed as a 
childhood/adolescent disorder.1ADHD frequently begins between [ADDRESS_1012847] commonly  diagnosed between 7 and 10 y earsof age . The diagnosis and 
treatment of ADHD of a very  young child represents a diagnostic challenge.4Because 
inattention, impulsivity ,and hy peractivity  can all be normal behaviors for a y oung child, 
making a diagnosis of ADHD often requires the degree and impairment of these 
symptoms to be bey ond what is developmentall y appropriate.5
It is wide ly believed that the core s ymptoms in ADHD result from d ysregulation in the 
balance of 2 neurotransmitter sy stems in the prefrontal cortex, ie, norepi[INVESTIGATOR_238] 
(noradrenaline) and dopamine.6,7,8
Cent anafadine (EB- 1020), which is an inhibitor of the uptake of norepi[INVESTIGATOR_238] , 
dopamine, and serotonin (5
-hydroxytryptamine) in vitro and in vivo, is a novel drug
candidate that is being dev eloped as a treatment for ADHD in adults ( ≥ 18 years) and in 
children (4 to 17 years, inclusive).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
18

Protocol 405 -201-[ZIP_CODE]
19
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul 2019Please refer to the centanafadine Investigator’s Brochure ( IB)for more detailed 
information.9
2.1 Trial Rationale
Currently , the PK of centanafadine administered as IR/XR capsules is being evaluated in 
adults. I t is possible that the PK (particularly  absorption) of centanafadine following 
administration of the XR formulation may  be different in children as compared to adults 
due to phy siological differences in the gastro intestinal tract. Therefore, the primary  
purpose of this trial is to evaluate the PK of centanafadine  following 
administration of centanafadine capsule s
in pediatric subjects (9 to 12 years, inclusive) 
with ADHD and determine if the X R formulation is appropriate for further evaluation. 
2.2 Background
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
19

Protocol 405 -201-[ZIP_CODE]
20
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul 2019 
 
 
 
 
 
 
2.2.2 Clinical
Centanafadine has been evaluated in 9 clinical trials (7 phase 1 trials and 2 phase 2 trials).
 
 
Refer to the IB for more information.9
 
 
 
 
 
 
 
 Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
20

Protocol 405 -201-[ZIP_CODE]
22
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012848] and as ymptom atic; 
however, h ypertension, tach ycardia, and orthostasis have occurred. During clinical trials, 
heart rate and blood pressure should be measured prior to initiation of therapy  and 
periodicall y while on therap y. Subjects should also be monitored for tach ycardia or 
hypertension. Centanafadine should be used with caution in subjects with hy pertension, 
tachycardia, or cerebrovascular disease or cardiovascular disease (eg, known serious 
structural cardiac abnormalities, cardiom yopath y, serious heart rh ythm abno rmalities, or 
other serious cardiac problems that may
 place a subject at increased vulnerability  to 
noradrenergic effects).
Skin rashes ranging from mild pruritic rash, maculopapular rash to diffuse ery thematous 
maculopapular rash have been observed in subjects who received multiple doses of 
centanafadine.
One subject experienced mild rash that was considered related to treatment after taking 
[ADDRESS_1012849] eted the trial. Eight subjects reported rash after multiple 
doses of centanafadine SR. Rashes resulted in discontinuation of dosing for 5 subjects 
and dose interruption and/or dose reduction for [ADDRESS_1012850] ( IMP)ranged from 
moderate to severe.
The majority  of subjects who experienced rash were exposed to centanafadine doses 
greater than 400 mg/day (2 subjects received 800 mg/day ,4 subjects received 
600mg/day ,and 2 subjects received 400 mg/day ). Neither subject who received 
400mg/day  discontinued dosing due to the rash nor were the rashes in these subjects 
consistent with the drug eruptions seen in subjects who received [ADDRESS_1012851] current version as needed.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
22
Protocol 405 -201-[ZIP_CODE]
24
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul [ZIP_CODE] Trial Design
4.1 Type/Design of Trial
This is a pi[INVESTIGATOR_32731] 2a, multicenter, open -label, single -dose trial in pediatric subjects 
(9to 12 y ears, inclusive) with a documented history  of ADHD and confirmation of an
ADHD prescription medication. This trial consists of a screening period (Day  
−21 to 
Day −2), check -in (Day  −1 or Day  1), 2-day treatment period (Day  1: dosing, Day  2: 
end-
of-treatment [ EoT]),and a safet y follow-up tele phone call 7 (+ 2) days after dosing
(Day 8).The screening period may  be e xtendedif additional time is needed to complete 
screening procedures , upon discussion with and approval by  [CONTACT_7195].
Written informed consent will be freel y obtained from all subjects’ guardian(s) or legall y 
acceptable representative(s), as applicable for local laws. Written informed assent will be 
freely obtained from all subjects. 
Eligible subjects will check -in eithe r on Day  −1 or Day  1, based on the investigator’s 
decision. A single dose of centanafadine will be administered either as intact capsule sor 
the capsule contents 
sprinkled on a tablespoon of applesauce on Day  1 in the morning. 
 
 Pharmacokinetic 
and safet y assessments will be performed for approximately  24 hours postdose. Subjects 
may be released from the clinic after PK sample collection at 12 hours postdose to return 
the following morning or may  remain in the clinic until 24 hours postdose, based on the 
investigator’s decision. Subjects released on Day  [ADDRESS_1012852] the clinic on Day  2 after 
EoT assessments and PK sampling are complete. 
Subjects and/or their caregivers will be contacte d by [CONTACT_756] [ADDRESS_1012853] concomitant medications.
A schematic of the trial design is provided in Figure 
1.2-1.
4.2 Scientific R ationale for Trial Design
A single dose is expected to be predictive of multiple dosing ;therefore ,this trial will 
evaluate a single dose of centanafadine. The focus is on the evaluation of the 
centanafadine concentration -time profile through 12 hours pos tdose and measuring 
centanafadine concentrations at 24 hours postdose to determine the potential for 
accumulation following multiple doses ;therefore , PK sampling through 24 hours is 
sufficient .Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
24

Protocol 405 -201-[ZIP_CODE]
25
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul [ZIP_CODE].3 Dosing Rationale
In adults, dosing is started at a 200 mg TDD administered in divided doses, 5 hours apart
,
using SR tablets; this regimen has been well tolerated. The 200 mg dose of  
produced centanafadine concentrations approximately  75% of the 200 mg TDD of SR. 
Inthis trial, a dose of 5 mg of IR beads and 50 mg of  beads will be administered ,
as the approximate median weight of 10 -and 11- year-old pediatric subjects is 35 kg, 
based on the Centers for Disease Control and Prevention (CDC) growth charts.10As 
75kg is the approximate weight of adults from phase [ADDRESS_1012854]- treatment follow -up electronic case report form ( eCRF )page for 
the last subject completing or withdrawing from the trial.
4.5 Definition of Comple
ted Subjects
The treatment period is defined as the time period during which subjects are evaluated for 
primary  and/or secondary  objectives of the trial irrespective of whether or not the subject 
actuall y consumed all doses of the IMP. Subjects who are evaluated at the last scheduled 
visit during the treatment period will be defined as trial completers. For purposes of this 
trial, subjects who complete Day [ADDRESS_1012855] of males and females, aged 9 to 12 years (inclusive)
,
who have a documented history  of ADHD and confirmation of anADHD prescription 
medication .
Up to [ADDRESS_1012856] identifier  
upon providing consent /assent. 
The s itenumber will be 
designated b y the sponsor. The subject number will be given sequentially from  as 
the serial numbers in the trial sites.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
25

Protocol 405 -201-[ZIP_CODE]
26
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul 2019Demographic information (collection date, date of birth, sex, childbearing potential, race, 
ethnicity ) and medica l history  will be recorded in the 
eCRF at the s creening visit.
5.2 Eligibility  Criteria
Exceptions for eligibility criteria will not be permitted during the trial, neither b y the 
investigator 
nor b y the medical monitor .
5.2.1 Inclusion Criteria
Subjects are required to meet thefollowing inclusion criteria at the time points described 
in the schedule of assessments ( Table 1.3-1).
1)
Written informed consent obtained from a legally  acceptable representative (eg, 
parent/guardian) and assent obtained from the subject prior to the initiation of an y 
trial-related procedures. The subject must provide informed assent at screening 
and must be able to understand that he or sh e can withdraw from the trial at any  
time. All informed consent/assent procedures must be in accordance with the trial 
site’s institutional review board (IRB)and local regulatory requirements.
2)Ability , in the opi[INVESTIGATOR_871], of the subject and the subject’s legall y 
acceptable representative (eg, parent/guardian) or caregiver(s) to understand the 
nature of the trial and follow protocol requirements, including the prescribed 
dosage regimens and discontinuation of prohibited concomitant medicatio ns, to 
reliably
 return for scheduled visits, and to be reliably  rated on assessment scales.
3)Male or female subjects 9 to 12 y ears of age, inclusive, at the time of informed 
consent/assent.
4)Subjects with good ph ysical health, as determined by  [CONTACT_740886], prior to enrollment in the trial:
Medical history
Clinical laboratory  determination
Electrocardiograms ( ECGs )
Physical examinations
5)Subjects with documented history  of ADHD and confirmation of anADHD 
prescription medication.
6)For female subjects of childbearing potential (defined as post -menarche) who are 
also sexually  active and male subjects who are sexually  active, the ability  to 
commit to remain fully  abstinent (periodic abstinence [eg, calendar, ovulation, 
symptothermal, p ostovulation methods] or withdrawal are not acceptable methods 
of contraception) or use 2 approved methods of birth control during the trial and 
for 30 day s following 
dosing .
7)Subject is judged b y the investigator to be clinically stable and has not had any
psychiatric hospi[INVESTIGATOR_300286] 12 weeks.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
26
Protocol 405 -201-[ZIP_CODE]
2
7
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul [ZIP_CODE].2.2 Exclusion Criteria
Subjects will be excluded if they  meet any of the following exclusion criteria at the time 
points described in the schedule of assessments ( Table 1.3-1).
1)Female subjects who are breast -feeding and/or have a positive pregnancy  test 
result prior to receiving IMP.
2)Subjects with a clinical presentation or history
 that is consistent with delirium, 
dement ia, amnesia, or other cognitive disorders; subjects with psychiatric 
symptoms that are better accounted for by  [CONTACT_740887](s) or 
direct effect of a substance (ie, medication, illicit drug use, etc.).
3)Subjects with a history  of intelle ctual disability  as determined b y at least 1 of the 
following: an intelligence quotient ( IQ)< 70, or clinical evidence, or a social or 
school history  that is suggestive of an intellectual disability .
4)Subjects who have an y of the following:
Asignificant risk of committing suicide based on history  and the principal 
investigator ’s clinical judgment, or routine psychiatric status examination
Current suicidal behavior
Imminent risk of injury  to self
Active suicidal ideation as it is evidenced b y an answer of “y es” on 
Questions 4 or 5 (over the last 6 months) on the suicidal ideation section of 
the “Baseline/Screening” version of the Columbia -Suicide Severit y Rating 
Scale (C-SSRS )
Any lifetime history  of suicidal behavior detected by  [CONTACT_941] “Baseline/ Screening”
version of the C -SSRS
The subject should not be enrolled (eg, dosed) if any  active suicidal ideation is 
present prior to dosing (as evidenced b y a clinical examination or an answer of 
“yes” on Questions 4 or 5 of the C -SSRS “Since Last Visit” ve rsion) or suicidal 
behavior is present in the C -SSRS “Since Last Visit” version.
5)Subjects with a lifetime history  of a substance use disorder (as determined by  [CONTACT_740888], 5th edition [DSM -5] 
criteria), or current substance misuse including alcohol and benzodiazepi[INVESTIGATOR_1651], but 
excluding caffeine and nicotine.
6)Subjects with hy pothy roidism or hy perthy roidism (unless the condition has been 
stabilized with medications for at least 90 day s prior to dosing with theIMP) or 
an abnormal result for free thyroxine ( T4)at screening. The e ligibility  of subjects 
excluded based on an abnormal free T4 result can be discussed with the medical 
monitor if, in the investigator’s judgment, the subject is a suitable candidate for 
the trial. (Note: free T4 is measured onl y if the result for thy roid-stimulating 
hormone [ TSH ]is abnormal.)Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
27
Protocol 405 -201-[ZIP_CODE]
28
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul [ZIP_CODE])Subjects who currently  have clinicall y significant neurological, dermatological, 
hepatic, renal, metabolic, hematological, immunological, cardiovascu lar, 
pulmonary , or gastrointestinal disorders such as any  history  of m yocardial 
infarction, congestive heart failure, human immunodeficiency  virus (HIV )
seropositive status/a cquired immunodeficiency  syndrome (AIDS), or chronic 
hepatitis B or C. Medical con ditions that are minor or well- controlled may  be 
considered acceptable if the condition does not expose the subject to an undue 
risk of a significant AEor interfere with assessments during the course of the 
trial. The medical monitor should be contact[INVESTIGATOR_530] i n any  instance where the 
investigator is uncertain regarding the stability  of a subject’s medical condition(s) 
and the potential impact of the condition(s) on trial participation.
8)Subjects with insulin -dependent diabetes mellitus (ie, an y subjects using in sulin).
9)Subjects with epi[INVESTIGATOR_231289] a history  of seizures (except for a single seizure epi[INVESTIGATOR_1865], 
for instance childhood febrile seizure or post traumatic) or a history  of severe 
head trauma (eg, concussion with loss of consciousness) or cerebrovascular 
disease (eg, stroke, transient ischemic attack, etc.).
10)Any major surgery  within 30 day s prior to dos ing with the IMP.
11)Any history  of significant bleeding or hemorrhagic tendencies.
12)Blood transfusion within 30 day s prior to dosing with the I MP.
13)Subjects wit h a positive drug screen for cocaine, marijuana (even if b y 
prescription), or other illicit drugs, or alcohol ,are excluded and may  not be 
retested or rescreened. Subjects with a positive urine drug screen resulting from 
the confirmed use of prescription o r over-the-counter medications or products that 
in the investigator’s documented opi[INVESTIGATOR_740878] a clinical condition that 
would impact the safet y of the subject or interpretation of the trial results may  
continue evaluation for the trial, following consultation and approval b y the 
medical monitor.
14) The following laboratory test and ECG results are exclusionary:
Platelet count ≤ 130 × 103/ μL
Hemoglobin ≤ 11.2 g/dL
Absolute neutrophil count ≤ 1.00 × 103/ μL
White blood cell count ( WBC )≤ 4.35 × 103/μL
Aspartate aminotransferase ( AST )> 2 × upper limit of normal ( ULN )
Alanine aminotransferase (ALT) > 2 × ULN
Creatine phosphokinase (CPK )> 2× ULN, unless discussed with and 
approved b y the medical monitor
Creatinine ≥ 0.7 mg/dL
QT interval corrected for heart rate using Fridericia’s formula (QTcF )
≥ 450 msec for more than 1 of the 3 ECGs performed for subjects < 12 years 
oldor QTcF ≥ 460 msec for more than 1 of the 3 ECGs performed for subjects 
≥12 years old
.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
28
Protocol 405 -201-[ZIP_CODE]
30
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul [ZIP_CODE].3.2 Caffeine, A lcohol, and Tobacco
The c onsumption of alcohol is prohibited 
within 72 hours prior to dosing and through the 
end of the 24- hour assessments .The use of tobacco following dosing through the end of 
the 24- hour assessments is prohibited.
5.3.3 Activity
Subjects will be asked to abstain from strenuous phy sical activity  for 48 hours prior to 
check -in and for the duration of the dosing period and PK sampling period; subjects 
should also not start any new supplements during the trial.
5.[ADDRESS_1012857] from whom informed consent /assent is obtained and is 
documented in writing (ie, subject signs an informed consent form [ ICF] or assent form ), 
but who is not randomized or assigned trial treatment. Subjects who sign an I CFor assent 
form but who are not started on treatment are permitted to be rescreened. Subjects with a 
positive drug screen for cocaine, marijuana (even if by  [CONTACT_50246]), or other illicit drugs, 
or alcohol ,may not be retested or rescreened; however, s ubjects excluded for other 
reasons may  berescreened at any  time, at the discretion of the medical monitor, if the 
exclusion characteristic has changed or resolved. In the event that asubject is rescreened 
for trial participation, and the rescreening is not completed within the original 
protocol -
specified screening period, a new I CF and assent form must be signed and 
screening procedures repeated .
If the subject meets the definition of a screen failure in this trial, the following 
information will be recorded in the eCRF :
Date of informed consent /assent
Visit date (screening visit)
Demographics (collection date, birth date, sex, race, ethnicit y, country)
Result of eligibility  assessment
Screen failure date
Reason for screen failureClinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
30
Protocol 405 -201-[ZIP_CODE]
31
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012858]
For full details on IMP management, please refer to the centanafadine IB.9Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
31

Protocol 405 -201-[ZIP_CODE]
32
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012859] will be provided to the investigators and the persons 
designated b y the investigator(s) or institution(s) by [CONTACT_92717]. The 
 Each will be labeled to cle arly disclose the 
compound ID, trial number, sponsor’s name [CONTACT_3816], instructions for use, route of 
administration, and appropriate precautionary  statements
.
6.2.[ADDRESS_1012860] of IMP ( ie, 
centanafadine ) received, dispensed, administered, and destro yed. Neither the investigato r 
nor an y designees may provide I MP to any  subject not participating in this protocol.
6.2.4 Returns and Destruction
The IMP will be destro yed by [CONTACT_169037]. The IMP may  only  be destroy ed by 
[CONTACT_21655](s), if approved by  [CONTACT_740889] I MP destruction meets all local 
regulations. Accountability  of the IMP must be completed and verified b y the assigned 
trial monitor prior to destruction. The trial site(s) may  utilize qualified third -party 
vendors for IMP destruction.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
32

Protocol 405 -201-[ZIP_CODE]
34
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul 2019Pi[INVESTIGATOR_499] (if available)
Availability  for return
[IP_ADDRESS] Return Process
Indicate during the report of the PQC if the complaint sample is available for return. If 
the 
complaint sample is available for return, return it in the product retrieval package, 
which will be provided by  [CONTACT_456].
It must be documented in the site accountabilit y record that a complaint sample for a 
dispensed kit has been forwarded to th e sponsor for complaint investigation.
[IP_ADDRESS] Assessment/Evaluation
Assessment and evaluation of PQCs will be handled by  [CONTACT_456].
6.3 Measures to Minimize/A void Bias
This is an open -label trial.
6.[ADDRESS_1012861] from 
30days prior to signing of informed consent /assent through the end of the evaluation 
period (defined as the time per iod during which subjects are evaluated for primary  and/or 
secondary  objectives) on the eCRF. The investigator will also record all medications and 
therapi[INVESTIGATOR_32546] b y the subject for treatment of an AE or which caused an AE until the end 
of the trial (defi ned as the last date of contact [CONTACT_444467]) on the 
eCRF.
For concomitant medications, the following will be recorded in the eCRF: medication, 
indication, dose, frequency , route, start date ,and end date. For concomitant therap y, the 
following will be recorded in the eCRF: therap y, indication, start date ,and end date.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
34
Protocol 405 -201-[ZIP_CODE]
35
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul 2019 
 
 
 
 
6.5.2 Permitted Medications
Not applicable.
6.5.3 Rescue Medications
Not applicable.
6.6 Intervention after the End of the Trial
Not applicable.
7 Stoppi[INVESTIGATOR_1869], Withdraw al Criteria, and Procedures
7.1 Entire Trial or Treatment
If the sponsor terminates or suspends the trial for any reason, prompt notification will be 
given to investigators, IRBs, and regulatory  authorities in accordance with regulatory  
requirements.
7.2 Individual Site
Individual trial site participation may  be discontinued by  [CONTACT_456], the investigator, or 
the IRBif 
judged to be necessary  for medical, safety , regulatory , ethical ,or other reasons 
consistent with applicab le laws, regulations, and good clinical practice ( GCP ). The 
investigator will notify  the sponsor promptly  if the trial is terminated by  [CONTACT_740890].
7.[ADDRESS_1012862] Discontinuation
7.3.1 Treatment Interruption
Not applicable.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
35

Protocol 405 -201-[ZIP_CODE]
36
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul [ZIP_CODE].3.2 Treatment Discontinuation
As this is a single -dose tria l, treatment discontinuation is not applicable. S ubjects 
who 
discontinue from the trial should be encouraged to complete all early  termination (ET) 
and follow -up assessments with ET assessments conducted as soon as possible after the 
subject is withdrawn.
7.3.[ADDRESS_1012863] may  discontinue from the trial for thereasons listed below:
Adverse event
Subject decides to discontinue because of anno yance or discomfort due to a 
nonserious AE which is not otherwise determined to be an undue hazard
SAE
Other potentially  IMP-related safety  concerns or AEs
Death
Lost to follow -
up
Physician decision
Pregnancy (Section 10.3)
Protocol deviation
Protocol violation
Protocol -specific withdrawal criterion met
Recovery
Site terminated by  [CONTACT_3211]
Trial 
terminated b y sponsor
Technical problems
Withdrawal by  [CONTACT_7078]/guardia n
Withdrawal by  [CONTACT_1130]
Other
If the subject discontinues from the trial due to an AE, the investigator, or other trial 
personnel, will make every  effort to follow the event until it has resolved or stabilized.
Follow -up procedures in Section 7.3.[ADDRESS_1012864] be followed.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
36
Protocol 405 -201-[ZIP_CODE]
37
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012865] the right to withdraw their consent
/assent from further participation in 
the trial at an y time without prejudice. Subjects ca nnot withdraw consent /assent for use of 
data alread y collected as part of the trial, but onl y for future participation. The 
investigator can also discontinue a subject’s participation in the trial at any  time if 
medically  necessary .Unless the subject or t he subject’s legall y acceptable representative 
(eg, parent/guardian) provides their written withdrawal of consent /assent , or there is other 
written documentation by  [CONTACT_444470]’s verbal intent to 
completely
 withdraw from the tri al, subjects should be followed for all protocol- specified 
evaluations and assessments, if possible .
Complete withdrawal of consent /assent requires a subject ’s or a subject’s legall y 
acceptable representative ’s(eg, parent/guardian) refusal of ALL of the f ollowing 
methods of follow-up:
Participation in all follow -up procedures specified in the protocol (whether in- clinic, 
by [CONTACT_756], or by  [CONTACT_28920] -home visit).
Participation in a subset of protocol specified follow -up procedures (by  a frequency  
schedule and method, as agreed by  [CONTACT_330210]).
Contact [CONTACT_81835] b y trial personnel, even if only  by [CONTACT_756], to assess current 
medical condition ,and obtain necessary  medical or laboratory  reports relevant to the 
trial’s objectives.
Contact [CONTACT_740891] e person(s) who have been designated in source records as being 
available to discuss the subject’s medical condition, even if onl y by [CONTACT_756], mail, 
or e-mail (eg, famil y, spouse, partner, legal representative, friend, neighbor, or 
physician).
Access to medical information from alternative sources (eg, hospi[INVESTIGATOR_307]/clinic medical 
records, referring doctor’s notes, public records, dialy sis, transplantation or vital 
registries, social media sources).
Withdrawal of consent /assent is a critical trial event and , therefore , should be approached 
with the same degree of importance and care as is used in initially  obtaining informed 
consent /assent .The reasons for a subject’s intended withdrawal need to be completely  
understood, documented , and managed to protect the rights of the subject and the 
integrit y of the trial. A subject may  initially  express their desire to discontinue from the 
trial.As such , the investigator should follow the procedures outlined in Section 7.3.[ADDRESS_1012866] can continue participation in the trial if modifications to his/her 
schedule of assessments can be accommodated. Only  subjects who withdraw their 
permission for all of the above methods of follow -up are considered to have completel y 
withdrawn their consent /assent 
to participate in the trial.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
37
Protocol 405 -201-[ZIP_CODE]
38
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul [ZIP_CODE].3.5 Procedures to Encourage Continued Trial Participation
In all cases of impending trialdiscontinuation or withd
rawal of consent/ assent , 
investigators will be instructed to meet and discuss (without undue coercion) with the 
subject , and the subject’s legally  acceptable representative (eg, parent/guardian), their 
options of continuing in the trial. The investigator should ensure understanding and 
documentation of the reasons for the subject’s desire to withdraw consent /assent .
7.[ADDRESS_1012867] to Follow -up
Subjects who cannot be contact[CONTACT_674545] 8(+ 2 day s) or subjects who do not 
have a known re ason for discontinuation (eg, withdrew consent /assent or AE) during the 
treatment period will be classified as “lost to follow -up”.
The site will make [ADDRESS_1012868] via certified mail or an alternative similar method, where appropriate, before 
assigning a “lost to follow -up” status.
If the subject was classified as “lost to follow -up”, “Were you able to contact [CONTACT_1560]?”, “Date of contact/Date of final contact [CONTACT_103904]”, and “Contact [INVESTIGATOR_12183]” will be 
recorded in the source documents .
[ADDRESS_1012869]’s participation in the trial will be approximately  29(+ 2) days in duration 
and will c onsist of a screening 
period (Day  −21 to Day  −2), check -in (Day  −1or Day  1), 
2-day treatment period (Day  1: dosing, Day  2: EoT) ,and a safet y follow- up telephone 
call 7 (+2) days after dosing (Day  8).
The total duration of the trial is expected to be approximately  3 months.
The assessments to be conducted during the trial are summarized
 in Table 1.3-1.
8.1
Efficacy  Assessments
Not applicable.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
38
Protocol 405 -201-[ZIP_CODE]
39
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul 2019 
 
 
 
 
 
8.2.1 Pharmacokinetic Blood Samples
Blood samples 
(4 mL , dipotassium ethy lenediaminetetraacetic acid [K 2EDTA ]) will be 
collected on Day  1 (1, 2, 3, 4, 6, 8, 10 and 12 hours postdose ) and on Day  2 (one PK 
sample between 22 to 26 hours postdose ),and will be processed into plasma for the 
determination of centanafadine, EB- [ZIP_CODE],  
 
 The actual date and time of the PK 
sample collection will be recorded in the eCRF. When vital signs or ECGs are scheduled 
at the same nominal time as PK sample collections, vital signs should be measured and 
ECGs should be performed before PK samples are collected.
After processing into plasma, aliquots will be placed into appropriatel y labeled tubes and 
will be placed in a freezer set at −70°C, unless otherwise instructed in the 
Operations/Labor atory  Manual.
All plasma samples will be shipped to the bioanaly tical laboratory for analy sis.
Additional information will be provided in the Operations/Laboratory  Manual .
8.3 Pharmacody namic Assessments
Not applicable.
8.4 Pharmacogenomic A ssessments
Not applicable.
8.5 Biomarker A ssessments
Not applicable.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
39

Protocol 405 -201-[ZIP_CODE]
40
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul [ZIP_CODE].6 Future Biospecimen Research Samples
Not applicable.
8.7
Safety  Assessments
Safety  assessments in this trial include AEs, clini cal laboratory  tests, phy sical 
examinations, vital signs, ECGs, and the C- SSRS.
Details pertaining to the definitions, collection, reporting, and follow -up of AEs are 
described in Section 8.8.
8.7.1 Clinical Laboratory  Assessments
Clinical laboratory  samples will be collected at the time points described in the schedule 
of assessments ( Table 1.3-1) to perform the clinical laboratory  assessments described in 
Section
10.2. Refer to Section 10.[ADDRESS_1012870] be reviewed b y the investigator prior to 
initiation of the administration of the IMP. Additional urine and blood samples may be 
collected for further evaluation of safet y as warranted by [CONTACT_093]’s judgment. 
Reports from the central laboratory  will be assessed by  [CONTACT_740892] .
8.7.2 Physical Examinatio n
A com plete p hysical examination will be performed at the time points described in the 
schedule of assessments ( Table 1.3-1 ).The complete phy sical examination will include 
height (screening onl y), weight, and calculation of body  mass index (BMI) as well as 
assessment of the head, eyes, ears, nose, and throat ;thorax ;abdomen
;skin and mucosae ;
neurological ;and extremities. Directed phy sical examinations in response to reported 
AEswill be conducted as necessary .Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
40
Protocol 405 -201-[ZIP_CODE]
41
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012871] be listed on the 
Food 
and Drug Administration ( FDA ) Form [ADDRESS_1012872] -screening abnormali ties considered b y the investigator to be clinically  
significant are to be recorded as AEs on the AE eCRF.
8.7.3 Vital Signs
Vital signs ( include systolic and diastolic blood pressure andheart rate ) will be collected 
at the time points described in the schedule of assessments ( Table 1.3-1). Subjects should 
be monitored for potentially  clinicall y significant vital signs values (Section 10.6).
Blood pressure and heart rate measurements will be made in the supi[INVESTIGATOR_572577] [ADDRESS_1012873] followed b y the standing measurements.
8.7.4 Electrocardiogram
Electrocardiograms will be performed at the time points described in the schedule of 
assessments ( Table 1.3
-1). Subjects should be monitored for potentiall y clinically 
significant ECG results (Section 10.7). Any abnormalities considered b y the investigator 
to be clinically  significant are to be recorded as AEs on the AE eCRF.
The 12
-lead ECGs will be performed in the supi[INVESTIGATOR_2547]. Predose 12- lead ECGs 
conducted at check -in (Day  −1 or Day  1)will be performed in triplicate, taken at least 
1minute apart following a 10-minuterest in the supi[INVESTIGATOR_2547] . The average of the 
3values will be the baseline value. Based on the QT cF, a subject will be excluded if the 
correction is 
≥ 450 msec for mor e than 1 of the 3 time points of triplicate predose ECGs 
performed for subjects < 12 years old or ≥ 460 msec for more than 1 of the 3 time points 
of triplicate predose ECGs performed for subjects ≥12 years old .
A central ECG service will be utilized for r eading all ECGs in order to standardize 
interpretations for the safety  anal ysis. In addition, ECG results will be evaluated at the 
trial site to monitor safety during the trial.
8.7.5 Suicidality  Monitoring
Suicidality  monitoring will occur at the time points de scribed in the schedule of 
assessments ( Table 1.3-1 ).Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
41
Protocol 405 -201-[ZIP_CODE]
42
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012874]. Documentation of trial training should be maintained in the trialsite’s files.
The “Baseline/Screening” version of the C -SSRS will be completed at the screening visit 
and the“Since Last Visit” version of the C -SSRS will be completed at check -in (Day −1
or Day 1)and EoT /ET. There are required items to be completed, potential additional 
items if there is a positive response to a required item, and items for suicide/suicide 
behavior present during the interview. The C- SSRS uses dichotomous scales (ie, y es or 
no), L ikert sc ales, and text or narrative to further describe the thoughts or behaviors .
8.7.[ADDRESS_1012875] and unintended response to 
an IMP related to an y dose administered.
A suspected adverse reaction is any  AE for which there is a reasonable possibility  that the 
IMP caused the AE. For the purpose of Investigational New Drug ( IND)safety  reporting, 
“reasonable possibility ” means there is evidence to suggest a causal relationship between 
the IMP and the AE. Suspected adverse reaction implies a lesser degree of certaint y about 
causality .
Treatment -emergent AEs (TEAEs) are defined as AEs with an onset date on or after the 
start of open -label treatment. In more detail, TEAEs are all AEs thatstarted after the start 
ofopen -label IMP treatment; or if the event wa s continuous from baseline and was 
worsening, serious, IMP related, or resulted in death ordiscontinuation from the trial .Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
42
Protocol 405 -201-[ZIP_CODE]
43
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul 2019An SAE includes an y event that results in any of the following outcomes:
Death
Life-threatening; ie, the subject was, in the opi[INVESTIGATOR_871], at i mmediate
risk of death from the event as it occurred. It does not include an event that, had it
occurred in a more severe form, might have caused death.
Persistent or significant incapacity /disability or substantial disruption of the ability  to
conduct normal life functions.
Requires inpatient hospi[INVESTIGATOR_34908].
Hospi[INVESTIGATOR_740879] s hould not be reported as an SAE; whenever possible the
reason for the hospi[INVESTIGATOR_92657] .
Hospi[INVESTIGATOR_92658] (ie, those
required for reasons of convenience or other nonmedical need) are not considered
SAEs .
Prescheduled hospi[INVESTIGATOR_444438] a condition that has existed prior to the
signing of the ICF and assent form should not be considered an SAE.
Congenital anomal y/birth defect.
Other medicall y significant events that, based upon appropriate medical judgment,
may jeopardize the subject and may  require medical or surgical intervention to
prevent one of the outcomes listed above; eg, allergic bronchospasm requiring
intensive treatment in an emergency  room or home, blood dyscrasias or convulsions
that do not result in hospi[INVESTIGATOR_059], or the development of drug dependency or dru g
abuse.
Nonserious AEs are all AEs that do not meet the criteria for a "serious" AE.
Adverse Events of Special I nterest (AESIs) : A noteworthy  event for the particular 
product/IMP or class of products that a sponsor may wish to monitor carefully . All AESIs 
are to be reported as immediatel y reportable events ( IREs).
Immediately  Reportable Event (IRE):
Any SAE
Any AE related to occup ational exposure
Any AESI s (see Section 8.8.5 )
Potential serious hepatotoxicity (see Section 8.8.6 )
Pregnancies are also defined as IREs. Although normal pregnancy  is not an AE, it
will mandate trialdiscontinuation and must be reported on an IRE form and the
Pregnancy  Surveillance Form(s) to the sponsor. Pregnancy  will only be documented
on the AE eCRF if there is an abnormality  or complication. This includes pregnancy
of the subject or the partner of the subject.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
43
Protocol 405 -201-[ZIP_CODE]
44
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012876] Value Chang es:It is the investigator’s responsibility  to review 
the results of laboratory  tests for each individual subject as they  become available. This 
review will be documented by  [CONTACT_093]’s dated signature [CONTACT_35217].
The investigator may  repeat the laboratory  test or request additional tests to verify  the 
results of the original laboratory  tests. If this laboratory value is considered medically 
relevant (ie, clinicall y significant) by  [CONTACT_093] ( subject is sy mptomatic, requiring 
corrective treatment or further evaluation ), or if the laboratory  value leadsto 
discontinuation, and/or fulfills a seriousness criterion, this is considered an AE. 
Severity :
Adverse events will be graded on a 3-point scale and reported as indicated on 
the e CRF .The severit y of an adverse experience is defined as follows:
1 = Mild: Discomfort noticed, but no disruption to daily  activity .
2 = Moderate: Discomfort sufficient to reduce or affect normal daily  activit y.
3 = Severe: Inability  to work or perform no rmal daily  activity .
IMP Causalit y:Assessment of causal relationship of an AE to the use of the IMP is 
defined as follows:
Related : There is a reasonable possibility  of a temporal and causal 
relationship between the IMP and the AE.
Not Related : There is no temporal or causal relationship between the I MP and 
the AE.
8.8.2 Eliciting and Reporting A dverse Events
The investigator will regularly assess subjects for the occurrence of AEs. To avoid bias in 
eliciting AEs, subjects should be asked the non leading question: “How have y ou felt 
since y our last visit? ” AllAEs (serious and nonserious) reported b y the subject must be 
recorded on the source documents and eCRF provided by  [CONTACT_456]. Adverse event
collection willbegin after a subject signs the ICFand assent form .
Medical terminology  should be used for AE reporting. Adverse events should be reported 
as a single unify ing diagnosis whenever possible or, in the absence of a unify ing 
diagnosis, as individual signs or s ymptoms.
Exacerbation or disease progression should be reported as an AE onl y if there are 
unusual or severe clinical features that were not present, or experienced earlier, or not 
expected based on the course of the condition.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
44
Protocol 405 -201-[ZIP_CODE]
45
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012877] be notified immediately b y telephone, fax, or e
-mail of an y 
IREs according to the procedure outlined below, in Section 8.8.3. Special attention 
should be paid to recording hospi[INVESTIGATOR_740880].
The AE, s tart date (and start time, if possible) , end date (and end tim e, if possible) , 
seriousness, 
severity , relationship to trialtreatment (IMP causalit y), action taken with 
trialtreatment ,and outcome will be recorded on the source documents an d in the eCRF .
8.8.[ADDRESS_1012878] immediately
 report (within 24 hours), using an IRE form, after 
he/she or site personnel become aware of an y IRE (SAE, AE related to occupational 
exposure, AESI , potential serious hepatotoxicity , or confirmed pregnancy ), by [CONTACT_756], 
fax, or e- mail to the sponsor or designee using the contact [CONTACT_444477] (Please note that the I RE form is NOT the AE e CRF .).
8.8.4 Medical Device Incidents (Including Malfunctions)
Not applicable.
8.8.[ADDRESS_1012879] irri tation at ECG 
lead sites due to application/removal of lead adhesive.
Refer to the separate rash workup plan for complete details, including reporting forms, 
and extra measures that must be performed to characterize an y skin AESI  of a newl y 
acquired skin e ruption that is nontraumatic . The trial site will have a local designated 
dermatologist available for immediate consultation during the trial for these AESIs.
All AESI s should be reported as IREs (see Section 8.8.3).
8.8.[ADDRESS_1012880] or ALT that is 
≥ 3times the ULN , a 
total bilirubin level should also be eva luated. If the total bilirubin is ≥[ADDRESS_1012881], 
complete an IRE form with all values listed and also report as an AE on the eCRF .
8.8.7 Procedure for Breaking the Blind
This trial does not use blinding procedures.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
45
Protocol 405 -201-[ZIP_CODE]
46
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul [ZIP_CODE].8.8 Follow -up of A dverse Events
[IP_ADDRESS] Follow -up of Nonserious A dverse Events
Nonserious AEs that are identified at an y time during the trial must be recorded on the 
AE eCRF with the current status 
(ongoing or resolved/recovered) noted. All nonserious 
events (that are not IREs) that are ongoing at the last scheduled contact [CONTACT_92705] .For an y AE having been identified throughout the trial, during 
analysis, additional relevant medical history  information may be requested by [CONTACT_331675]  (including, but not limited to, information such as 
risk-related behavior, family  history ,and occupation).
[IP_ADDRESS] Follow -up of Immediately  Reportable Events
This trial requires that subjects be activel y monitored for IREs up to 7 (+ 2) daysafter 
dosing.
Immediately  reporta ble events that are 
identified or ongoing at the last scheduled 
contact [CONTACT_331676]. If updated 
information (eg, resolved status) on IRE status becomes available after a subject’s last 
scheduled contact , this must be reported to the sponsor and recorded on the AE eCRF 
page and the IRE form , according to the appropriate reporting procedures described in 
Section 8.8.3.
It is expected that the investigator will provide or arrange appropriate supportive care for 
the subject and will provide prompt updates on the subject’s status to the sponsor .The 
investigator will follow 
IREs until the events are:
Resolved,
Stabilized,
The subject is lost to follow -up, or
Has died
.
Resolution means that the subject has returned to the baseline state of health and 
stabilized means that the investigator does not expect an y further improvement or 
worsening of the subject’s condition. The investigator will continue to report any  
significant follow -up information to the sponsor up to the point the event has resolved or 
stabilized, or the subject is lost to follow -up or has died.
Refer to Section 10.3 for additional information regarding the follow-up period for 
subjects that become pregnant or for pregnant partners of male subjects.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
46
Protocol 405 -201-[ZIP_CODE]
47
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012882] to follow -up or has died.
8.9 Treatment of Overdose
For treatment of overdose, please refer to IB Section 6.4 (Overdose).
8.[ADDRESS_1012883] or the capsule 
contents sprinkled on a tablespoon of applesauce.
 
 
 
 
9 Statistical Considerations
9.1 Sample Size
Since this is an exploratory  trial, no formal sample size calculations w ill be performed. 
Up to 12subjects may be treated depending on the concentration data and the number of 
subjects completing through 24 hours
.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
47

Protocol 405 -201-[ZIP_CODE]
48
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012884] 1 postdose evaluable plasma concentration.
The safet y dataset will include a ll subjects who receive 
thesingle dose of centanafadine .
9.3 Handling of Missing Data for Primary and Other Endpoint A nalysis
No data imputation will be performed for missing PK data in this trial. The handling of 
concentrations below the lower limit of quantitation will be according to the sponsor’s 
data handling processes.
9.[ADDRESS_1012885] measurement prior to the dosing of IMP.
[IP_ADDRESS] Adverse Events
All AEs will be coded b y system organ class and Medical Dictionary  for Regulatory  
Activities (MedDRA) preferred term. The incidence of the following events will be 
summarized:
TEAEs
TEAEs by [CONTACT_11370] y
TEAEs potentially  causally  related to the IMP
TEAEs with an outcome of death
Serious TEAEs
TEAEs leading to discontinuation from the trial
The TEAEs will also be presented in a listing.
[IP_ADDRESS] Clinical Laboratory  Data
Descriptive statistics will be used to summarize the change from baseline for laboratory  
tests. The i ncidence of potentially  clinical lyrelevan t laboratory  tests will be summarized 
by [CONTACT_7206] . Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
48
Protocol 405 -201-[ZIP_CODE]
49
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul [ZIP_CODE].4.2.3 Physical Examination and Vital Signs Data
A listing of ph ysical examination result
swill be provided.
Descriptive statistics will be used to summarize the change from baseline for vital signs. 
The i ncidence of potentially  clinical lyrelevan t vital signs will be summarized by  [CONTACT_74056] .
[IP_ADDRESS] Electrocardiogram Data
Descriptive statistics will be used to summarize the change from baseline for ECG s. The 
incidence of 
potentially  clinical lyrelevan t ECGs will be summarized by  [CONTACT_7206] .
[IP_ADDRESS] Other Safety  Data
[IP_ADDRESS].1 Columbia
-Suicide Severity Rating Scale
Suicidality  will be assessed based on the C -SSRS (“Baseline” Version and “Since Last 
Visit” Version). The incidence of suicidality , suicidal behavior ,and suicidal ideation will 
be summarized descriptively  by [CONTACT_740893] a listing .
9.4.3 Other A nalyses
[IP_ADDRESS] Analysis of Demographic and Baseline Characteristics
Baseline demographic characteristics including age, race, ethnicit y, sex, weight, height, 
and BMI will be summarized by  [CONTACT_740894] . 
Baseline disease characteristics and psy chiatric history  will be also summarized by  
[CONTACT_9086].
[IP_ADDRESS] Pharmacokinetic A nalysis
A noncompartmental analy sis will be performed. Plasma concentrations of centanafadine
and metabolite (s)will be summarized by  [CONTACT_740895] (intact 
capsule sor capsule contents sprinkled on a tablespoon of applesauce). The PK 
parameters will be summarized by  [CONTACT_740896].
No inferential statistical anal ysis will be conducted.
The following PK parameters will be summarized:
Maximum ( peak )plasma concentration (C max) of centanafadine
Time to maximum concentration (t max) of centanafadine
Area under the concentration- time curve from time 0 to 12 hours postdose (AUC 0 -12h)
of centanafadineClinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
49
Protocol 405 -201-[ZIP_CODE]
51
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul 201910 Supporting Documentation and Operational Consideratio ns
10.1 Appendix 1: Regulatory , Ethical, and Trial Oversight 
Considerations
10.1.[ADDRESS_1012886] be conducted in compliance with the protocol, FDA regulations ,
International Council for Harmonisation (ICH)GCP :Consolidated 
Guideline (E6), 
international ethical principles derived from the Declaration of Helsinki and Council for 
International Organizations of Medical Science (CIOMS) guidelines, and applicable local 
laws and regulations. Each trial site will seek approval/favorable opi[INVESTIGATOR_740881] , and the investigator will provide that documentation 
to the sponsor .The IRB will evaluate the ethical, scientific ,and medical appropriateness 
of the trial. Further, in preparing and handling the eCRF , the invest igator, 
subinvestigator , and their staff will take measures to ensure adequate care in protecting 
subject privacy .To this end, a subject ID will be used to identify  each subject.
Financial aspects, subject insurance ,and the publication policy  for the tri al will be 
documented in the agreement between the sponsor and the investigator.
10.1.[ADDRESS_1012887] be able to understand that he or she can 
withdraw from the trial at any  time and for an y reason .
Each ICF will comply  with the I CH GCP :Consolidated Guideline E612and local 
regulatory  requirements. The investigator will ensure that the sponsor reviews and 
authorizes any  written site - specific ICF used in the trial be fore submission to the IRB. In 
support of the site’s standard process for administering informed consent, this trial will 
also allow for electronic informed consent (eICF) as a tool within applicable regions and 
trial sites. The eICF utilizes the I RB-approved site -speci fic ICF to offer subjects an 
enhanced platform to review and understand their rights as a research subject as well as 
required trial procedures. When possible, trial sites will have subjects and their guardian 
or legally  acceptable representative review an d sign the eICF prior to starting an y trial 
procedures; however ,
if local regulations do not allow for use of the electronic format, 
subjects may  continue in the trial utilizing the standard paper and wet ink signature 
[CONTACT_41705].Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
51
Protocol 405 -201-[ZIP_CODE]
52
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012888] obtaining 
consent /assent .However, informed consent
/assent must be obtained and documented 
before initiation of an yprocedures that are performed solely  for the purpose of 
determining eligibility  for this trial, including withdrawal from current medication(s).
Potential subjects and their guardian or legally acceptable representative are free to refuse 
entry  into the trial, or withdraw from the trial at any time, without justification, and there 
will be no consequences to their further care.
Prospective trial subjects will be provided with controlled access to the eICF application 
by [CONTACT_444485]. When the trial si te staff , subject, and the subject’s guardian or legally  
acceptable representative agree that the subject and the guardian or legall y acceptable 
representative has enough information to make an informed decision to participate, the 
subject’s guardian or legally  acceptable representative will electronically  sign in the eICF 
application and an electronic date and timestamp will be applied to the signature ; the 
subject will sign the assent form in the eICF application and an electronic date and 
timestamp wil l be applied to the signature . The subject and the subject’s guardian or 
legally  acceptable representative will be given a printed, signed cop y of the I CFand 
assent . Any other parties required b y the IRB(trial site staff, witnesses, or legally  
authorized representative) are also required to sign electronically  and these signatures 
will be stored with the eICF in accordance with the I CH GCP guideline and local 
regulatory  requirements/guidelines. These signatures cannot be altered, removed, or 
copi[INVESTIGATOR_530].
Once appropriate essential information has been provided and full y explained in 
layman’s language to the subject and the subject’s guardian or legally  acceptable
representative by [CONTACT_093] (or a qualified designee), and it has been documented 
that the subject and the subject’s guardian or legally  acceptable representative has had the 
opportunity  to ask questions, the IRB-approved written I CFand assent will be signed and 
dated b y the subject’s guardian or legally  acceptable representative and subject , 
respectivel y,and the person obtaining consent /assent (investigator or designee), as well 
as by  [CONTACT_740897]. The subject the subject’s guardian or legall y 
acceptable representative will receive a cop y of the signed ICFand assent ; the original 
shall be kept on file b y the investigator.
Subjects and their guardian or legall y acceptable representative may  be asked to sign 
additional I CFs or give additional assent if the protocol is amended and the changes to 
the protocol result in additional information that needs to be provided to the subjects and 
their guardian or legall y acceptable representative , so that they  can make a Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
52
Protocol 405 -201-[ZIP_CODE]
53
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012889] partner and fetus.
10.1.3 Confidentiality
All information generated in this trial will be considered confidential and will not be 
disclosed to any one not directly  concerned with the trial without the sponsor’s prior 
written permission. Subject confidentialit
y requirements of the region(s) where the trial is 
conducted will be met. However, authorized regulatory  officials and sponsor personnel 
(or their representatives) may be allowed full access to inspect and copy  the records, 
consistent with local requirements. All IMP, subject bodily  fluids, and/or other materials 
collected shall be used so lely in accordance with this protocol, unless otherwise agreed to 
in writing b y the sponsor.
Subjects will be identified only  by [CONTACT_740898] e CRF .If further subject 
identification is required, subjects’ full names may be made known to a regul atory  
agency  or other authorized officials if necessary , subject to local regulations .
10.1.4 Quality  Control and Quality  Assurance
[IP_ADDRESS] Monitoring
The sponsor has ethical, legal, and scientific obligations to follow this trial in accordance 
with established research principles, the ICH GCP :Consolidated Guideline (E6), and 
applicable regulatory  requirements and local laws. As part of a concerted effort to fulfill 
these obligations (maintain current personal knowledge of the progress of the trial), the 
sponsor's monitors will visit the site during the trial, as well as communicate frequently  
via telephone, e -mail, and written communications. In addition, all investigators and trial 
sitepersonnel will undergo initial and ongoing training for this particular trial, and t his 
training will be clearl y documented.
[IP_ADDRESS] Auditing
The sponsor's Qualit y Assurance Unit (or representative) may conduct trial site audits.
Audits will include, but are not limited to, I MP supply , presence of required documents, 
the informed consent/assent process, and a review of the e CRF with source documents, as 
applicable .The investigator agrees to participate with audits.
Regulatory  authorities may  inspect the investigator site during or after the trial. The 
investigator will cooperate with such inspections and will contact [CONTACT_458226].Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
53
Protocol 405 -201-[ZIP_CODE]
54
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul 201910.1.5 Protocol Deviations
In the event of a significant deviation from the protocol due to an emergency, accident, or 
mistake (eg, violation of the 
informed consent /assent process, IMP dispensing or subject 
dosing error, treatment assignment error, subject enrolled in violation of eligibility  
criteria or concomitant medication criteria), the investigator or designee will contact [CONTACT_740899] e -mail.The 
investigator and sponsor (or designee) will come as quickly  as possible to a joint decision 
regarding the subject’s continuation in the trial. This decision will be documented by  [CONTACT_51243] (or designee) and reviewed by  [CONTACT_25007].
Any major protocol deviation will be recorded in the eCRF along with the start date and 
details of the deviation.
10.1.6 Records Management
[IP_ADDRESS] Source Documents
Source documents are defined as the results of original observations and a ctivities of a 
clinical investigation. Source documents will include but are not limited to medical 
records , electronic data, screening logs, and recorded data from automated instruments.
All source documents pertaining to this trial will be maintained b y the investigators and 
made available for direct inspection by  [CONTACT_92718].
Investigator(s)/institution(s) will permit trial- related monitoring, audits, IRBreview, and 
regulatory  inspection(s) by  [CONTACT_20618]/documents by  
[CONTACT_35086] I CF.In all cases, subject confidentiality  must be 
maintained in accordance with local regulatory  requirements.
[IP_ADDRESS] Data Collection
During each subject’s visit to the site, an investigator or their designee 
participating in the 
trial will record information to document all significant observations. At a minimum, 
these notes will contain:
Documentation of the informed consent/assent process, including any  revised 
consents /assents ;
Documentation of the investigator’s decision to enroll the subject into the trial, the 
review of all inclusion/exclusion criteria prior to IMP administration, and 
confirmation of the subject’s actual participation in the trial;
The date of the visit and the corresponding Visit or Day  in the trial schedule;
General subject status remarks, including an y significant medical findings. The 
severit y, frequency, duration, action taken, and outcome of an y AEs and the 
investigator's assessment of relationship to I
MP must also be recorded;Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
54
Protocol 405 -201-[ZIP_CODE]
55
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul 2019Any changes in concomitant medications or dosages;
A general reference to the procedures completed; 
The signature (or initials) and date of the investigator (or designee) who made an 
entry  in the medical record .
In addition, any  contact [CONTACT_92719].
Source documents and source data will be captured electronically  (where permitted by  
[CONTACT_1295]) in this trial a nd will meet the same fundamental elements of data qualit y 
(eg, attributable, legible, contemporaneous, original, and accurate) as paper records. 
These data will be collected into a sy stem that is fully  validated according to 21 Code of 
Federal Regulations (CFR
)Part11. Changes to the data will be captured by [CONTACT_740900].
Designated trial site staff will not be given access to the electronic source system until 
they have been appropriately  trained. Information to be originall y captured and reviewed 
electronically  shall include details of the subject visit and the protocol -required 
assessments performed as a part of these visits, medical history , AEs, and concomitant 
medications. Because this trial is using an electronic source record as the ori ginal point of 
data capture, there is no additional data entry  step for the trial site for data collected 
directly  into the application, rather, the electronic source record directl y populates the 
trial database.
Some data may  be captured via paper and then entered into the eSource s ystem. These 
and an y other data treated in this manner will be source data verified per the monitoring 
plan and the location of the source data (ie, eSource, paper, or a local electronic sy stem) 
will be documented before the tri al start. An y changes to information in paper source 
documents will be initialed and dated on the day  the change is made by a trial site staff 
member authorized to make the change. Changes will be made b y striking a single line 
through erroneous data (so a s not to obliterate the original data), and clearly  entering the 
correct data (eg, wrong data right data). If the reason for the change is not apparent, a 
brief explanation for the change will be written in the source documentation by  [CONTACT_92685] t heir designee.
Another exception will be safet y laboratory or central ECG data, where the official 
source documentation will be considered the report issued by  [CONTACT_92720] .Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
55
Protocol 405 -201-[ZIP_CODE]
56
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012890] ;however ,
on-site monitoring inspections will continue to take place in order to review data entry  of 
source documentation directly  captured on paper and transcribed into the s ystem, to 
ensure protocol adherence, to assess trial site operational capa bilities
,and to perform 
other monitoring activities that cannot be performed remotely.
At the end of the trial, the investigator must certify that the data entered into the eSource 
application are complete and accurate. After database lock, the investigator will receive 
an electronic copy of the subject data.
[IP_ADDRESS] File Management at the Trial Site
The investigator will ensure that the trial site file is maintained in accordance with 
Section 8 of the I CH GCP: Consolidated Guideline ( E6)and as required by [CONTACT_713530]. The investigator/institution will take measures to prevent accidental or 
premature destruction of these documents.
[IP_ADDRESS] Records Retention at the Trial Site
The FDA regulations require all investigators participating in clinical drug trials to 
maintain detailed clinical data for one of the following periods:
A period of at least 2 y ears after the date on which a New Drug Application is 
approved b y the FDA;
A period of [ADDRESS_1012891] not dispose of an y records relevant to this trial without either 
(1)written permission from the sponsor or (2) provision of an opportunity  for sponsor to 
collect such records. The investigator wil l be responsible to maintain adequate and 
accurate electronic or hard copy  source documents of all observations and data generated 
during this trial including any  data clarification forms received from the sponsor. Such 
documentation is subject to inspection by  [CONTACT_92721].
If the investigator withdraws from the trial (eg, due to relocation or retirement), all 
trial-related records should be transferred to a mutually  agreed -upon designee within a 
sponsor -specified timefra me.Notice of such transfer will be given to the sponsor in 
writing.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
56
Protocol 405 -201-[ZIP_CODE]
57
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012892] of this trial 
will be based on International Committee of Medical Journal E ditors (I CMJE) authorship 
criteria (http://www.icmje.org/recommendations). According to ICMJE guidelines, one 
may be considered an author only  if the following criteria are met:
1)Substantial contributions to the conception or design of the work; or the 
acqu isition, analy sis, or interpretation of data for the work; AND
2)Drafting the work or revising it criticall
y for important intellectual content; AND
3)Final approval of the version to be published; AND
4)Agreement to be accountable for all aspects of the work in ensuring that questions 
related to the accuracy  or integrit y of an y part of the work are appropriately 
investigated and resolved.
All authors must meet the above criteria, and all who qualify  for authorship based on the 
above criteria should be listed as authors.
Investigators or other trial subjects who do not qualify  for authorship may  be 
acknowledged in publications resulting from the trial. By  [CONTACT_92726], investigators or other trial subjects consent to such acknowledgement in any  
publications resulting from its conduct.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
57
Protocol 405 -201-[ZIP_CODE]
58
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul 201910.2 Appendix 2: Clinical Laboratory  Tests
The tests detailed in Table 10.2-1 will be performed.
Table 10.2-1 Clinical Laboratory Assessments
Hem atology:
Hem atocrit
Hem oglobin
Platelet count
Mean corpuscular hemoglobin
Mean corpuscular hemoglobin concentration
Mean corpuscular volume
RBC c ount
WBC count with differential
Microscopic u rinalysis:
Appearance
Bilirubin
Color
Glucose
Ketones
Leukocyte esterase
Leukocytes
Nitrites
Occult blood
pH
Protein
Urobilinogen
Specific gravity
Microscopic analysis of RBC/WBC ,per high 
powered field (casts, crystals, squamous cells)
Additional Tests:
TSH, w ith reflex to free T4 if TSH is abnormal
HBsAg
anti-HCV
HIV
Serum hCG/urine test pregnancy (for all female 
subjects ≥12 years of age and female subjects
<12years of age who have started menstruati ng)Serum Chemistry:
Albumin
ALP
ALT
AST
Bicarbonate
Bilirubin, total
BUN
Calcium
Carbon dioxide
Chloride
Cholesterol (total, HDL, LDL)
CPK
Creatinine
GGT
Glucose
LDH
Magnesium
Phosphorus
Potassium
Protein, total
Sodium
Uric acid
Triglycerides
Drug Screen (all items in urine except where 
noted) :
Alcohol (breath or urine)
Amphetamines
Barbiturates
Benzodiazepi[INVESTIGATOR_740882] (urine or serum)
Marijuana
Methadone
Opi[INVESTIGATOR_740883] =alkaline phosphatase; anti-HCV =hepatitis C antibodies; BUN =blood urea nitrogen; 
GGT =gamma glutamyl transferase; HBsAg =hepatitis B surface antigen; hCG =human chorionic 
gonadotropin; HDL = high -density lipoprotein; LDH =lactic dehydrogenase; LDL = low -density 
lipoprotein; RBC=red blood cell count .Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
58
Protocol 405 -201-[ZIP_CODE]
59
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul 201910.3 Appendix 3: Contraceptive Guidance and Collection of Pregnancy  
Information
Females of child bearing potential ( FOCBP) are females
≥12 years of age and females 
<12 years of age whose menstruation has started and who are not docum ented as sterile 
(eg, have had a bilateral oophorectom y, or h ysterectomy , or who have been 
postmenopausal for at least 12 months).
For males and FOCBP, who are sexually  active, there must be a documented agreement 
that the subject and their partner will ta ke effective measures (ie, 2different approved 
methods of birth control or remains full y abstinent ) to prevent pregnancy  during the 
course of the trial and for 30 day s after dosing . Periodic abstinence ( eg, calendar, 
ovulation, sy mptothermal, postovulation methods )or withdrawal are not acceptable 
methods of contraception . Unless the subject is sterile (ie, females who have had a 
bilateral oophorectomy , have had a hy sterectomy , or have been postmenopausal for at 
least 12 consecutive months; or males who have had a bilateral orchiectomy) or remains 
fully  abstinent during the trial and for [ADDRESS_1012893] be used: vasectom y, tubal ligation, intrauterine device, 
birth control pi[INVESTIGATOR_3353], bi rth control implant, birth control depot injection, condom with 
spermicide, sponge with spermicide, or occlusive cap (vaginal diaphragm or 
cervical/vault cap) with spermicide. Any single method of birth control, including 
vasectom y and tubal ligation, may fail, leading to pregnancy . The contraceptive method 
will be documented in the eCRF .Male subjects must also agree not to donate sperm from 
trial screening through 30daysafter dosing .
Before enrolling males and females 
in this clinical trial, investigato rs must review the 
below information about trial participation as part of the I CF and assent process. The 
topi[INVESTIGATOR_34911] y include:
General information
Informed consent or assent form
Pregnancy  prevention information
Drug interactions with hormonal contraceptives
Contraceptives in current use
Follow -up of a reported pregnancy
Before trial enrollment, males and F OCBP (and their guardian or legall y acceptable 
representative) must be advised of the importance of avoiding pregnancy  during trial 
participation and the potential risk factors for an unintentional pregnancy .Subjects and Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
59
Protocol 405 -201-[ZIP_CODE]
60
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012894] for human chorionic gonadotropin (hCG) will be 
performed at screening and check- in to the inpatient facility on all FOCBP (female 
subjects ≥ 12 years of age and all female subjects < 12 years of age, if menstruation has 
started). If a urine test is performed and is positive, the investigator will follow- up with a 
confirmatory  serum test.
The i nvestigator (or appropriate trial site staff) is advised to counsel subject s (and their 
guardian or legally  acceptable representative ) on the risk of pregnancy  while participating 
in a clinical trial as well as ensuring that the subject understands how pregnancies occur 
and can be avoided. This should be documented in the source records.
During the trial, all FOCBP should be instructed to contact [CONTACT_92704] (eg, missed or late menstrual cy cle). Male subjects 
must be instructed to contact [CONTACT_43054] y, dur ing the trial, if their partner
suspect sthat they  might be preg nant (eg, missed or late menstrual cy cle).
If a subject is suspected to be pregnant before she receives IMP, the IMP administration 
must be withheld until the results of serum pregnancy  tests are available. If the pregnancy  
is confirmed, the subject must n
ot receive the IMP and must not be enrolled in the trial. If 
pregnancy  is suspected after the subject hastaken IMP, and the pregnancy  is confirmed
with serum pregnancy  test results, the subject wil l be withdrawn from the trial. 
Exceptions to trial discontinuation may  be considered for life -threatening conditions only  
after consultations with the IRE contact (see the title page of this protocol for contact 
[CONTACT_3031]).
The investigator must immediately  notify  the sponsor (within 24 hours) of any  pregnancy  
associated with IMP exposure during the trial and for at least 30days after dosing , and 
record the event on the IRE form and forward it to the sponsor. The sponsor will forward 
the Pregnancy  Surveillance Form(s) to the investigator for monitoring t he outcome of the 
pregnancy .
Protocol -required procedures for trial discontinuation and follow- up must be performed 
on the subject unless contraindicated b y pregnancy (eg, x -ray studies). Other appropriate 
pregnancy  follow -up procedures should be c onsidere d if indicated. In addition, the 
investigator must report to the sponsor, on the Pregnancy  Surveillance Form(s), 
follow -up information regarding the course of the pregnancy , including perinatal and 
neonatal outcome. Infants will be followed for a minimum o f 6 months from the date of 
birth.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
60
Protocol 405 -201-[ZIP_CODE]
62
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012895] Q uality  Complaint
QTc Corrected QT interval
QTcF QT interval corrected for heart rate using Fridericia’s formula
RBC Red blood cell count
SAE Serious adverse event
SR Sustained
-release
T4 Thyroxine
TDD Total daily  dose
TEAE Treatment -emergent adverse event
tmax Time to maximum concentration
TSH Thyroid- stimulating hormone
ULN Upper limit of normal
VAS Visual analogue scale
WBC White blood cell count
XR Extended -releaseClinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
62

Protocol 405 -201-[ZIP_CODE]
63
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul 201910.5 Appendix 5: Criteria for Identify ing Laboratory Values of Potential 
Clinical Relevance
Laboratory TestsCriteria (Norm al Ranges)
for Subjects [ADDRESS_1012896] ≥ 2 × ULN
ALT ≥ 2 × ULN
ALP ≥ 2 × ULN
BUN ≥24mg/d L (≤ 4 mg/dL or ≥24mg/dL )
Creatinine ≥ 0.7 mg/dL ( ≤ 0.2 mg/dL or ≥ 0.7 mg/dL )
Uric acid ≥ 6.7 mg/dL ( ≤ 1.6 mg/dL or ≥ 6.7 mg/dL )
Bilirubin (total) ≥ 1.6 mg/dL ( ≤ 0.2 mg/dL or ≥ 1.6 mg/dL )
CPK ≥ 2 × ULN
Prolactin ≥ 21.00 ng/dL ( ≤ 2.63 ng/dL or ≥ 21.00 ng/dL )
Hem atology
Hem atocrit ≤ 33% ( ≤ 33% or ≥ 44% )
Hem oglobin ≤ 11.2 g/dL ( ≤ 11.2 g/dL or ≥ 15.5 g/dL )
White blood count ≤4.35 ×103/μL(≤4.35 ×103/μLor ≥13.65 × 103/μL)
Eosinophils 4.8%
Neutrophils ≤ 40.5% ( ≤ 40.5% or ≥ 75.0% )
Absolute n eutrophil count ≤1.00 ×103/μLor ≥9.00 ×103/μL
Platelet count ≤130×103/μL(≤ 130 × 103/μLor ≥570 ×103/μL)
Urinalysis
Protein Change from baseline
Glucose Presence
Additional Criteria
Chloride ≤ 94 mEq/L or ≥112mEq/L
Potassium ≤3.3mEq/L or 5.2mEq/L
Sodium ≤ 132 mEq/L or ≥ 148 mEq/L
Calcium ≤8.3mg/d L or ≥ 10.9mg/dL
Glucose
Fasting ≥ 100mg/dL (≤70mg/dL or ≥ 100mg/dL )
Nonfasting ≥ 139mg/dL (≤59mg/dL or ≥ 139mg/dL )
Total c holesterol, fasting ≥217mg/dL (≤97mg/dL or ≥217mg/dL )
LDL cholesterol, fasting ≥ 130 mg/dL
HDL cholesterol, fasting ≤34mg/d L (≤34mg/dL or ≥75mg/dL )
Triglycerides, fasting ≥131mg/dL (≤30mg/dL or ≥131mg/dL )
aThe recommended criteria represented in this table are intended to identify on -treatment outside of 
norm al values that could potentially be clinically relevant. Variations based on local laboratory 
ranges may need to be considered.
bInformation adapted from: 1.Soghier L, Pham K, Rooney S. Reference Range Values for Pediatric 
Care . The Ameri can Academy of Pediatrics. 2014; 2.Hughes HK, Kahl LK. The Johns Hopkins
Hospi[INVESTIGATOR_307] : The Harriet Lane Handbook .21st edition. 2015 ; 3. Covance central laboratory reference 
ranges, 2019.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
63
Protocol 405 -201-[ZIP_CODE]
64
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul 201910.6 Appendix 6: Criteria for Identify ing Vital Signs of Potential Clinica l 
Relevance
Variable Criterion ValueaChange Relative to 
Baselinea
Heart rate at restb< 60 bpm or > 110 bpmIncrease or decrease of 
≥ 15 bpm
Systolic blood pressurec
School -age (6 to 9 years old)< 85 mmHg or > 115 mmHg Increase or decrease of 
≥20 mmHg
Preadolescent (10 to 12 
years old)< 90 mmHg or > 120 mmHg Increase or decrease of 
≥15 mmHg
Diastolic blood pressurec
School -age (6 to 9 years old)< 50 mmHg or > 80 mmHg Increase or decrease of 
≥15 mmHg
Preadolescent (10 to 12 
years old)< 60 mmHg or > 80 mmHg Increase or decrease of 
≥15 mmHg
Orthostatic hypotension≥30 mmHg decrease in systolic blood 
pressure and/or a decrease of 
≥20mmHg in diastolic blood pressure 
after at least 3 minutes of standing 
compared to the previous supi[INVESTIGATOR_740884] d 
pressureNot applicable
(baseline status not 
considered)
Orthostatic tachycardia≥25 bpm increase in heart rate from 
supi[INVESTIGATOR_628557]
(baseline status not 
considered)
Weight Not applicableIncrease or decrease of 
≥25%
bpm = beats per m inute.
aThe criterion value and change relative to baseline represented in this table are intended to identify 
on-treatment values outside of normal changes and that could potentially be clinically relevant. I n 
order to be identified as potentially clinically relevant, theon-treatment value must meet the 
“Criterion Value” and also represent a change from the subject’s baseline value of at least the 
magnitude shown in the “Change Relative to Baseline” column. When evaluating these values, the 
emotional state of the subject must be taken into consideration (eg, crying, screaming) and 
documented as applicable.
bInformation adapted from: Hughes HK, Kahl LK. The Johns Hopkins Hospi[INVESTIGATOR_307]: The Harriet Lane 
Handbook. 21s t edition. 2015.
cInformation adapted from: Flynn JT, Kaelber DC, Baker -Smith CM, et al. Clinical Practice Guideline 
for Screening and Management of High Blood Pressure in Children and Adolescents: American 
Academy of Pediatrics Subcommittee on Screening a nd Management of High Blood Pressure in 
Children. Pediatrics. 2017;140(3):1 -72.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
64
Protocol 405 -201-[ZIP_CODE]
65
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul 201910.7 Appendix 7: Criteria for Identify ing ECG Measurements of 
Potential Clinical Relevance13
Variable Criterion ValueaChange Relative to 
Baselinea
Rhythm
Sinus tachycardiab≥ 110 bpm increase of ≥15 bpm
Sinus bradycardiac≤ 60 bpm decrease of ≥15 bpm
Supraventricular premature beat all not present present
Ventricular premature beat all not present present
Supraventricular tachycardia all not present present
Ventricular tachycardia all not present present
Atrial fibrillation all not present present
Atrial flutter all not present present
Conduction
1atrioventricular block PR ≥ 200 msec increase of ≥50 m sec
2atrioventricular block all not present present
3atrioventricular block all not present present
Left bundle- branch block all not present present
Right bundle -branch block all not present present
Pre-excitation syndrome all not present present
Other intraventricular conduction blockdQRS ≥120 msec increase of ≥20 m sec
Infarction
Acute or subacute all not present present
Old all not present present
≥[ADDRESS_1012897]/T Morphological
Myocardial ischemia all not present present
Symmetrical T -wave inversion all not present present
Increase in QTc
< 12 years old
≥ 12 years oldQTcF ≥450 msec
QTcF ≥ 460 msecincrease of 60 msec 
from baseline
QTc = corrected QT interval .
aThe criterion value and change relative to baseline represented in this table are intended to identify 
on-treatment values outside of normal changes and that could potentially be clinically relevant. I n 
order to be identified as potentially clinically relevant, theon-treatment value mu st meet the 
“Criterion Value” and also represent a change from the subject’s baseline value of at least the 
magnitude shown in the “Change Relative to Baseline” column. When evaluating these values, the 
emotional state of the subject must be taken into con sideration (eg, crying, screaming) and 
documented as applicable.
bNo current diagnosis of supraventricular tachycardia, ventricular tachycardia, atrial fibrillation, atrial 
flutter, or other rhythm abnormality.
cNo current diagnosis of atrial fibrillation, atrial flutter, or other rhythm abnormality.
dNo current diagnosis of left bundle branch block or right bundle branch block.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
65
Protocol 405 -201-[ZIP_CODE]
66
Confid ential -Proprietary Information Amendment 1 Approval: 23 Jul 201910.8 Appendix 8: Protocol A mendments
The investigator will not make an y changes to this protocol without the sponsor’s prior 
written 
consent and subsequent approval/favorable opi[INVESTIGATOR_1686].Any permanent 
change to the protocol, whether an overall change or a change for specific trial site(s), 
must be handled as a protocol amendment. Any amendment will be written by [CONTACT_103]. Each amendment will be submitted to the IRB, as required by  [CONTACT_427].
Exce pt for “administrative” or “non substantial” amendments, investigators will wait for 
IRBapproval /favorable opi[INVESTIGATOR_331643](s). Administrative amendments are defined as having no effect on the safet y of 
subjects, conduct or management of the trial, trial design, or the quality or safet y of 
IMP(s) used in the trial. A protocol change intended to eliminate an apparent immediate 
hazar d to subjects should be implemented immediately after agreement b y the sponsor 
and investigator , followed by  [CONTACT_740901]. The 
sponsor will submit protocol amendments to the applicable regulatory  agencies within 
local applicable timelines .
When the IRB, investigators, and/or the sponsor conclude that the protocol amendment 
substantially  alters the trial design and/or increases the potential risk to the subject, the 
currentl y approved written I CF and assent form will req uire similar modification. In such 
cases, after approval /favorable opi[INVESTIGATOR_628558] I CFand assent form by [CONTACT_1201], repeat 
written informed consent /assent will be obtained from subjects enrolled in the trial and 
their guardian or legall y acceptable repre sentative before expecting continued 
participation and before the amendment -specified changes in the trial are implemented.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
66
Protocol 405 -201-[ZIP_CODE]
69
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012898] T, Coghill D. ADHD in children and y oung people: 
prevalence,care pathways, and service provision. Lancet Ps ychiatr y. 2018;5: 175
-186.
2Connor DF. Preschool attention deficit hy peractivity  disorder: a review of prevalence, 
diagnosis, neurobiology , and stimulant treatment. J Dev Behav Pediatr. 
2002;23:S1- S9.
3Egger HL, Angold A. Common emotional and behavioral disorders in preschool 
children: presentation, nosology, and epi[INVESTIGATOR_623] . J Child Psy chol Psy chiatry . 
2006;47:313 -337.
4Rappley  MD, Mullan PB, Alvarez FJ, Eneli IU, Wang J, Gardiner JC. Diagnosis of 
attention -deficit/hy peractivity  disorder and use of psy chotropic medication in very  
young children. Arch Pediatr Adolesc Med. 1999;153:[ADDRESS_1012899] VA, Marino T, Cole H, et al. Absence 
of gender effects on attention deficit hy peractivity  disorder: findings in nonreferred 
subjects. Am J Psy chiatry . 2005;162:1083 -1089. 
6Arnsten AF. Fundamentals of attention- deficit/hy peractivit y disorder: circuits and 
pathway s. J Clin Psy chiatry . 2006;67(Suppl 8):7 -12.
7Heal DJ, Smith SL , Findling RL. ADHD: current and future therapeutics. Curr Top 
Behav Neurosci. 2012;9:361-390.
8Bolea -Alamañac B, Nutt DJ, Adamou M, Asherson P, Bazire S, Coghill D, et al. 
Evidence -based guidelines for the pharmacological management of attention deficit 
hyperactivit y disorder: update on recommendations from the British Association for 
Psychopharmacology . J Psy chopharmacol. 2014;28:179 -203.
9Otsuka Phar maceutical Development and Commercialization. Centanafadine 
(EB-1020) Investigator’s Brochure, Edition 8. Otsuka Report, issued 12 Mar 2019.
10Centers for Disease Control and Prevention. Weight- for-age charts, 2 to 20 y ears. 
Available at: https://www.cdc. gov/growthcharts/percentile_data_files.htm. Updated 
Aug 04, 2009. Accessed Mar 15, 2019.
11Abdulla S, Amuri B, Kabany wany i AM, Ubben D, Rey nolds C, Pascoe S, et al. Earl y 
clinical development of artemether -lumefantrine dispersible tablet: palatability  of 
three flavours and bioavailability  in healthy  subjects. Malar J. 2010;9:253. 
12International Council for Harmonisation (ICH) [homepage on the Internet]. E6(R2): 
Good Clinical Practice: Integrated Addendum to ICH E6(R1) [finalized 2016 
November; cited 2019 Apr 11]. Available from: 
https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/
E6/E6_R2__Step_4_2016_1109.pdf.
13Vink AS, Neumann B, Lieve KV, Sinner MF, Hofman N, Kadi S, et al. 
Determination and interpretation of the QT interv al. Comprehensive anal ysis of a 
large cohort of long QT sy ndrome patients and controls. Circulation. 
2018;138:2345-2358.Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
69
Protocol 405 -201-[ZIP_CODE]
70
Confid ential -Proprietary Information Amendment 1 Approval: [ADDRESS_1012900] read and understand the protocol (including the 
Investigator's Brochure) and agree that it contains all the ethical, legal and scientific information 
necessary to conduct this trial in accordance with the principles of Good Clinical Practices and as 
described herein and in the sponsor's (or designee's) Clinical Trial Agreement.
I will provide copi[INVESTIGATOR_35008], nurses, and other professional personnel to 
whom I delegate trial responsibilities. I will discuss the protocol with them to ensure that they are 
sufficiently informed regarding the investigational new drug, centanafadine , the concurrent 
medications, the efficacy and safety parameters and the conduct of the trial in general. I am aware that 
this protocol must be approved by [CONTACT_4707] (IRB) responsible for such matters 
in the cli nical trial facility where centanafadine will be tested prior to commencement of this trial. I 
agree to adhere strictly to the attached protocol (unless amended in the manner set forth in the 
sponsor's Clinical Trial Agreement, at which time I agree to adh ere strictly to the protocol as 
amended).
I understand that this 
IRB-approved protocol will be submitted to the appropriate regulatory 
authority/ies by [CONTACT_456]. I agree that clinical data entered on eCRF by [CONTACT_331696], such as for submission to governmental regulatory authorities 
and/or in combination with clinical data gathered from other research sites, whenever applicable. I 
agree to allow sponsor and designee monitors and auditors full access to all medical records at the 
research facility for subjects screened or enrolled in the trial.
I agree to await IRB approval before implementation of any substantial amendments to this protocol. 
If, however, there is an immediate hazard to subjects, I w ill implement the amendment immediately, 
and provide the information to the IRB within the required local applicable timelines. Administrative 
changes to the protocol will be transmitted to the IRB for informational purposes only, if required by 
[CONTACT_155159].
I agree to provide all subjects with informed consent forms, as required by [CONTACT_331697]. I agree to report to the sponsor any adverse experiences in accordance with the 
terms of the sponsor's Clinical Trial Ag reement and the relevant regional regulation(s) and 
guideline(s). I further agree to provide all required information regarding financial certification or 
disclosure to the sponso r for all investigators and subinvestigators in accordance with the terms of the 
relevant regional regulation(s). I understand that participation in the protocol involves a commitment 
to publish the data from this trial in a cooperative publication before publication of efficacy and safety 
results on an individual basis may occur, and I consent to be acknowledged in any such cooperative 
publications that result.
____________________________ _____________________________ ___________
Principal Investigator [INVESTIGATOR_92673] 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
70
This page is a manifestation of an electronically captured signature
[CONTACT_35218]: 405-201-[ZIP_CODE] Protocol Amendment 1
Document Version: 3.0
Signed by [CONTACT_4232]
(dd-MMM-
yyyy hh:min) -
UTC timezone
Clinical Approval 23-Jul-2019
20:19:27
Biostatistics Approval 23-Jul-2019
22:40:58
Clinical Pharmacology
Approval23-Jul-2019
19:33:21Clinical Study Report 405-201-[ZIP_CODE] 16.1.1 Protocol and Protocol Amendments
Until the information herein is released by [CONTACT_35095], the contents of this document are Otsuka
confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.
71
